Risultati per: L’ereditarietà di 12 tipi di cancro

Annals of Internal Medicine, Ahead of Print.

Studio, una bevanda al giorno aumenta il rischio di 5 volte

Studio, una bevanda al giorno aumenta il rischio di 5 volte

Objectives
Telehealth may offer a cost-effective, accessible and convenient healthcare service model; however, the acceptability, safety and perceptions of telehealth delivered lifestyle interventions in those with non-alcoholic fatty liver disease (NAFLD) is unknown.

Design
This was a mixed-methods evaluation of a telehealth delivered 12-week exercise, dietary support and behavioural change programme (Tele-ProEx).

Setting and participants
12 adults receiving the intervention (47–77 years) with NAFLD living in Australia.

Outcome measures
Participants were assessed postintervention via questionnaires to evaluate acceptability and satisfaction with the programme, usability (exercise app) and perceptions of safety. Semistructured interviews were also conducted, and qualitative thematic analysis was used to identify themes.

Results
Participants reported moderate to high acceptability (overall mean±SD scores out of 5: exercise programme 3.9±0.5; dietary support to increase plant protein intake 4.0±0.7; behavioural modification 3.6±0.4). Satisfaction was high (overall mean score 3.7±0.3 out of 4), the programme was perceived as safe (overall mean score, 4.4±0.5 out of 5) and app usability was above average (mean score 75.6±5.2 out of 100). Thematic analysis revealed participants perceived telehealth as being comparable to face-to-face interactions with health professionals. Common exercise barriers were alleviated by the personalised programme, while participants with low previous exposure to plant protein foods found the dietary recommendations challenging. Social support and engagement were deemed important for supporting motivation and adherence.

Conclusions
In adults with NAFLD, a telehealth delivered multifaceted lifestyle programme was well accepted and perceived as safe, indicating telehealth offers a viable delivery model in this population. Key features important to participants were the personalised and flexible approach utilising engaging delivery methods that featured social support.

Trial registration number
ACTRN12621001706864.

Stroke, Ahead of Print. Neuroinflammation significantly contributes to stroke pathophysiology, leading to tissue damage and neurological deficits. Baicalein, a potent 12/15-LOX (12/15-lipoxygenase) inhibitor, demonstrates neuroprotective effects by reducing inflammatory lipid mediators, modulating key inflammatory pathways, and attenuating oxidative stress. Experimental studies indicate that baicalein can diminish infarct size and neurological deficits while improving safety and tolerability. Combination therapies with baicalein show promise in enhancing stroke outcomes. Overall, targeting 12/15-LOX and employing baicalein represents a promising approach to modulating neuroinflammation and improving recovery in stroke patients. This review highlights the therapeutic potential of inhibiting the 12/15-LOX pathway and utilizing the natural compound baicalein to mitigate poststroke neuroinflammation.

A causa delle infezioni da antibioticoresistenza occupati quasi 3 milioni di posti letto nel Paese

Ai primi test porta sviluppo di cellule immunitarie anti-tumore

Si rafforza collaborazione tra Istituti, verso progetti comuni

Objectives
To conduct a cost-utility analysis of an implementation package that has been developed aiming to embed the referral of people with type 2 diabetes mellitus (T2DM) to structured self-management education (SSME) from primary care into routine practice compared with usual care.

Design
Model-based cost-effectiveness analysis using the School for Public Health Research type 2 diabetes treatment model. With costs and effectiveness parameters coming from analyses of data from a cluster randomised control trial.

Setting
English National Health Service.

Participants
People with T2DM from 64 GP practices in England.

Interventions
Embedding SSME implementation package Usual care.

Primary and secondary outcome measures
The primary outcome measure was the incremental cost-effectiveness ratio. Secondary outcome measures included the probability of Embedding implementation package being cost-effective and value of information.

Results
The estimated cost of the intervention was £40 316 across the study sites, which equates to £0.521 per patient across all practices. For the base case, the estimated mean discounted incremental lifetime cost of the intervention per patient is £48.19. This is associated with a mean per patient incremental quality-adjusted life-year (QALY) estimate of 0.006, producing an incremental cost-effectiveness ratio of £8311 per QALY gained. This has a 73.1% probability of the intervention being cost-effective at a funding threshold of £20 000 per QALY gained. Scenario analyses indicate that alternative parameterisations can lead to this finding being overturned.

Conclusions
The effectiveness of the Embedding packages was hampered by the COVID-19 pandemic. However, our base case analysis shows that Embedding could be cost-effective for this patient population, but this was subject to significant structural uncertainty. This suggests that while implementation initiatives can be highly cost-effective in this population, more robust evidence or further incentivisation will be required before widespread adoption can be recommended.

Trial registration number
ISRCTN23474120, registered 05/04/2018.

L’organizzazione accoglie a Roma chi viene da fuori per le cure

E’ partner del progetto ‘European cancer imaging – Eucaim’